SUDA Submits Additional Data for ZolpiMist^TM to TGA, Expects the Completion of TGA Review by Q4 2020

May 12, 2020 12:53 PM AEST
Team Kalkine

In a latest update, oro-mucosal drug delivery player SUDA Pharmaceuticals Ltd (ASX:SUD) notified that the Therapeutic Goods Administration (TGA) review for ZolpiMist^TM is expected to be completed by Q4 2020, subject to the TGA feedback.

SUDA added that the TGA is continuing with the review of additional data submitted by the company for ZolpiMist^TM, which supports the quality of the product being produced using the new active pharmaceutical ingredient (API) supplier and manufacturer.

The Company will also share this data with its current and future partners to back their regulatory submissions.

SUD is trading with a rise of ~6.5 per cent at $0.049 as at 11:54 AM AEST on 12^th May 2020.

Disclaimer

The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.